Similarly, MRX-2843, a dual MerTK/Axl inhibitor, has shown preclinical synergy with checkpoint inhibitors in AML, gliomas, and ovarian cancer by blocking myeloid-driven immune suppression (130). Here, MERTK is linked to ovarian cancer.